DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lexapro (Escitalopram Oxalate) - Published Studies

 
 



Lexapro Related Published Studies

Well-designed clinical trials related to Lexapro (Escitalopram)

Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. [2012]

Effect of escitalopram on hot flash interference: a randomized, controlled trial. [2012]

No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression. [2012]

A review of escitalopram and citalopram in child and adolescent depression. [2011.11]

Escitalopram for the treatment of major depressive disorder in youth. [2011.10]

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. [2011.10]

Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. [2011.07]

Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. [2011.07]

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. [2011.06]

Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. [2011.05]

A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers. [2011.04.30]

Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. [2011.04.15]

Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. [2011.04]

Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. [2011.04]

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. [2011.03.01]

Efficacy of escitalopram compared to citalopram: a meta-analysis. [2011.03]

Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. [2011.02]

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. [2011.01.19]

Are old-old patients with major depression more likely to relapse than young-old patients during continuation treatment with escitalopram? [2011.01.14]

Escitalopram for the treatment of major depressive disorder in youth. [2011]

A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers. [2011]

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. [2010.12]

Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. [2010.11]

[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study]. [2010.10]

Efficacy of escitalopram compared to citalopram: a meta-analysis. [2010.09.29]

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. [2010.08.30]

Comparative bioavailability of two escitalopram formulations in healthy human volunteers. [2010.08]

Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. [2010.08]

Impact of escitalopram on nocturnal sleep, day-time sleepiness and performance compared to amitriptyline: a randomized, double-blind, placebo-controlled study in healthy male subjects. [2010.07]

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. [2010.07]

Escitalopram attenuates posterior cingulate activity during self-evaluation in healthy volunteers. [2010.05.30]

Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. [2010.05]

Urinary flow and urinary symptoms in elderly males exposed to either escitalopram or duloxetine. [2010.05]

Escitalopram prolonged fear induced by simulated public speaking and released hypothalamic-pituitary-adrenal axis activation. [2010.05]

Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. [2010.03]

Effect of escitalopram on the processing of emotional faces. [2010.03]

Escitalopram and enhancement of cognitive recovery following stroke. [2010.02]

Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. [2010.02]

Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study. [2010.02]

Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. [2010.01.15]

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. [2010.01]

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. [2010]

Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study. [2009.12]

Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. [2009.12]

Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. [2009.11]

Specific effects of escitalopram on neuroendocrine response. [2009.11]

Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. [2009.10.15]

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. [2009.09.30]

Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. [2009.09]

Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. [2009.09]

Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. [2009.08.11]

Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. [2009.07]

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). [2009.04.07]

Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. [2009.04]

Superiority of escitalopram to paroxetine in the treatment of depression. [2009.04]

Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. [2009.03]

The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype. [2009.03]

Escitalopram: an open-label study of bereavement-related depression and grief. [2009.02]

Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. [2009.01.21]

Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. [2009.01]

Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. [2009]

No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter. [2008.12.15]

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. [2008.12]

[Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression] [2008.11]

Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. [2008.11]

Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. [2008.10.15]

Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. [2008.10.03]

Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. [2008.09]

Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. [2008.06]

Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. [2008.05.28]

Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. [2008.05]

Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. [2008.04]

An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients. [2008.04]

Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. [2008.03]

Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. [2008.03]

Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. [2008.03]

Escitalopram in specific phobia: results of a placebo-controlled pilot trial. [2008.03]

Escitalopram effects on insula and amygdala BOLD activation during emotional processing. [2008.03]

Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. [2008.02.15]

Escitalopram in the acute treatment of depressed patients aged 60 years or older. [2008.01]

Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. [2008.01]

High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. [2008.01]

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. [2008]

Escitalopram and Duloxetine in Major Depressive Disorder: A Pharmacoeconomic Comparison Using UK Cost Data. [2008]

Bioequivalence of two commercial preparations of escitalopram oxalate/clonazepam using a liquid chromatography-electrospray mass spectrometry method. [2008]

An open-label trial of escitalopram in children and adolescents with social anxiety disorder. [2007.12]

Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial. [2007.10]

Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. [2007.10]

Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. [2007.10]

Escitalopram prevents relapse in older patients with major depressive disorder. [2007.07]

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. [2007.07]

Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. [2007.07]

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. [2007.07]

An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder. [2007.07]

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. [2007.06]

Escitalopram prevents relapse of obsessive-compulsive disorder. [2007.05]

Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. [2007.04]

Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. [2007.04]

Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. [2007.03]

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. [2007.02]

Escitalopram in the treatment of anxiety symptoms associated with depression. [2007]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012